199 related articles for article (PubMed ID: 27869781)
1. Molecular Docking Optimization in the Context of Multi-Drug Resistant and Sensitive EGFR Mutants.
García-Godoy MJ; López-Camacho E; García-Nieto J; Nebro AJ; Aldana-Montes JF
Molecules; 2016 Nov; 21(11):. PubMed ID: 27869781
[TBL] [Abstract][Full Text] [Related]
2. Solving molecular docking problems with multi-objective metaheuristics.
García-Godoy MJ; López-Camacho E; García-Nieto J; Aldana-Montes AJ
Molecules; 2015 Jun; 20(6):10154-83. PubMed ID: 26042856
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel drug-resistant EGFR mutant inhibitors by in silico screening using comprehensive assessments of protein structures.
Sato T; Watanabe H; Tsuganezawa K; Yuki H; Mikuni J; Yoshikawa S; Kukimoto-Niino M; Fujimoto T; Terazawa Y; Wakiyama M; Kojima H; Okabe T; Nagano T; Shirouzu M; Yokoyama S; Tanaka A; Honma T
Bioorg Med Chem; 2012 Jun; 20(12):3756-67. PubMed ID: 22607878
[TBL] [Abstract][Full Text] [Related]
5. A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation.
Akher FB; Farrokhzadeh A; Ravenscroft N; Kuttel MM
Biochemistry; 2019 Oct; 58(41):4246-4259. PubMed ID: 31589411
[TBL] [Abstract][Full Text] [Related]
6. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR
Zhang Z; Zou J; Yu L; Luo J; Li Y; Tu Z; Ren X; Wei H; Song L; Lu X; Ding K
Cancer Med; 2018 Apr; 7(4):1430-1439. PubMed ID: 29532998
[TBL] [Abstract][Full Text] [Related]
7. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Al-Anazi M; Al-Najjar BO; Khairuddean M
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
[TBL] [Abstract][Full Text] [Related]
8. Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors.
Bhandari SV; Kuthe PV; Patil SM; Nagras OG; Sarkate AP; Chaudhari SY; Surve SV
Chem Biodivers; 2023 Nov; 20(11):e202301081. PubMed ID: 37793119
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting two cellular mutant epidermal growth factor receptor tyrosine kinases by addressing computationally assessed crystal ligand pockets.
Lee JH; Lin WC; Wen TK; Wang C; Lin YT
Future Med Chem; 2019 Apr; 11(8):833-846. PubMed ID: 30724109
[No Abstract] [Full Text] [Related]
10. Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.
Wang A; Li X; Wu H; Zou F; Yan XE; Chen C; Hu C; Yu K; Wang W; Zhao P; Wu J; Qi Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Yun CH; Liu J; Liu Q
J Med Chem; 2017 Apr; 60(7):2944-2962. PubMed ID: 28282122
[TBL] [Abstract][Full Text] [Related]
11. Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
Günther M; Lategahn J; Juchum M; Döring E; Keul M; Engel J; Tumbrink HL; Rauh D; Laufer S
J Med Chem; 2017 Jul; 60(13):5613-5637. PubMed ID: 28603991
[TBL] [Abstract][Full Text] [Related]
12. Computational identification of new TKI as potential noncovalent reversible EGFR
Abdelmalek D; Smaoui F; Frikha F; Ben Marzoug R; Msalbi D; Souissi A; Aifa MS
J Biomol Struct Dyn; 2024 Jun; 42(9):4870-4887. PubMed ID: 37349947
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
Planken S; Behenna DC; Nair SK; Johnson TO; Nagata A; Almaden C; Bailey S; Ballard TE; Bernier L; Cheng H; Cho-Schultz S; Dalvie D; Deal JG; Dinh DM; Edwards MP; Ferre RA; Gajiwala KS; Hemkens M; Kania RS; Kath JC; Matthews J; Murray BW; Niessen S; Orr ST; Pairish M; Sach NW; Shen H; Shi M; Solowiej J; Tran K; Tseng E; Vicini P; Wang Y; Weinrich SL; Zhou R; Zientek M; Liu L; Luo Y; Xin S; Zhang C; Lafontaine J
J Med Chem; 2017 Apr; 60(7):3002-3019. PubMed ID: 28287730
[TBL] [Abstract][Full Text] [Related]
14. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
Li Y; Song Z; Jin Y; Tang Z; Kang J; Ma X
Molecules; 2016 Nov; 21(11):. PubMed ID: 27827863
[TBL] [Abstract][Full Text] [Related]
15. A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
Ai X; Sun Y; Wang H; Lu S
Amino Acids; 2014 Jul; 46(7):1635-48. PubMed ID: 24658966
[TBL] [Abstract][Full Text] [Related]
16.
Imana SN; Ningsih EG; Tambunan USF
Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
[TBL] [Abstract][Full Text] [Related]
17. Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.
Tomassi S; Lategahn J; Engel J; Keul M; Tumbrink HL; Ketzer J; Mühlenberg T; Baumann M; Schultz-Fademrecht C; Bauer S; Rauh D
J Med Chem; 2017 Mar; 60(6):2361-2372. PubMed ID: 28225269
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.
Yoshikawa S; Kukimoto-Niino M; Parker L; Handa N; Terada T; Fujimoto T; Terazawa Y; Wakiyama M; Sato M; Sano S; Kobayashi T; Tanaka T; Chen L; Liu ZJ; Wang BC; Shirouzu M; Kawa S; Semba K; Yamamoto T; Yokoyama S
Oncogene; 2013 Jan; 32(1):27-38. PubMed ID: 22349823
[TBL] [Abstract][Full Text] [Related]
19. Kinetic and thermodynamic insights into interaction of erlotinib with epidermal growth factor receptor: Surface plasmon resonance and molecular docking approaches.
Mohammadzadeh-Asl S; Aghanejad A; Yekta R; de la Guardia M; Ezzati Nazhad Dolatabadi J; Keshtkar A
Int J Biol Macromol; 2020 Nov; 163():954-958. PubMed ID: 32653374
[TBL] [Abstract][Full Text] [Related]
20. Molecular docking of novel 5-O-benzoylpinostrobin derivatives as wild type and L858R/T790M/V948R mutant EGFR inhibitor.
Pratama MRF; Poerwono H; Siswodihardjo S
J Basic Clin Physiol Pharmacol; 2019 Dec; 30(6):. PubMed ID: 31855568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]